Hepatic dysfunction resulting from hepatic veno-occlusive disease (VOD) is a common complication of bone marrow transplantation (BMT). Some investigators believe that hepatic dysfunction, along with pulmonary and central nervous system (CNS) dysfunction, is part of a systemic disorder called multiple organ dysfunction syndrome (MODS). Endothelial damage by pretransplant chemo-radiation and activation of hemostasis are considered early events in the development of hepatic VOD. The pathological mechanism leading to fibrous obliteration of hepatic vessels may also take place in pulmonary and CNS vessels. Since antiphospholipid antibodies (aPA) are associated with venous and arterial thrombosis, which can lead to vessel occlusion, we asked if the incidence of aPA before conditioning was greater in patients who developed MODS following BMT. Samples drawn before pretransplant chemo-radiation from 57 patients who subsequently developed MODS and 55 control patients who did not develop MODS were studied blindly for aPA by ELISA. The number of aPA-positive patients who developed MODS (10/57), compared to the number of aPA-positive patient controls who did not develop MODS (7/55) was not statistically significant (P = 0.48). Our data indicate that the incidence of aPA before conditioning was not greater in patients who developed MODS, including hepatic VOD, following BMT. Keywords: antiphospholipid antibodies; anticardiolipin antibodies; autoimmunity; thrombosis; hepatic veno-occlusive disease; multiple organ dysfunction syndrome Hepatic dysfunction resulting from hepatic veno-occlusive disease (VOD) is a common, often fatal complication of bone marrow transplantation (BMT). Endothelial damage due to pretransplant chemo-radiation and activation of hemostasis are considered to be early events in the development of hepatic VOD with the end result being fibrous obliteration of hepatic vessels.
factor VIII in hepatic vessels 2 are consistent with the decreased functional levels of protein C and antithrombin III (ATIII) in patients who develop hepatic VOD subsequent to transplantation. 1, 3, 4 The decrease prior to conditioning 1, 5, 6 suggests a deficiency which renders these patients susceptible to thrombosis and VOD prior to the chemo-radiation induced endothelial damage. The chemoradiation may exacerbate an underlying condition in these patients.
Antiphospholipid antibodies (aPA) are autoantibodies which are associated with venous and arterial thrombosis. 7, 8 aPA have been observed in patients with autoimmune diseases 9, 10 who are prone to thrombosis and subsequent organ damage/dysfunction as a result of vessel occlusion by fibrin thrombi. [11] [12] [13] [14] aPA also have been noted in patients with early failed renal allografts 15, 16 and cardiac allografts. 17 Vessels of failed cardiac and renal allografts have a similar fibrin deposition which is associated with a loss of endothelial ATIII in these grafts 18 and is partially responsible for the transplant-induced vascular sclerosis in the cardiac allografts. 19 aPA have been implicated in hepatic artery thrombosis, a common complication of liver transplantation, 20 and have been described in one hepatic VOD patient in whom lupus anticoagulant was detected following bone marrow transplantation. 21 Finally, aPA have been documented in patients with decreased protein C 22 and ATIII levels 23 as determined by functional assays. Several mechanisms exist by which aPA could be involved in the development of VOD. 24 aPA can bind and activate endothelial cells, thereby inducing a procoagulant state. 25 aPA are associated with accelerated thrombin generation following endothelial damage 26 perhaps because aPA can interfere with activation of protein C by the thrombinthrombomodulin complex. 26, 27 aPA also can strengthen the inhibitory effects that ␤2 glycoprotein I has on activated protein C. 28, 29 Because of the similarities between hepatic VOD and other vascular diseases with which aPA are associated and because of the mechanisms by which aPA could be involved in the development of VOD, we asked if the incidence of aPA prior to pretransplant chemo-radiation was greater in patients who developed organ dysfunction subsequent to BMT. Because there is evidence that hepatic dysfunction, along with pulmonary and CNS dysfunction, is part of a systemic multiple organ dysfunction syndrome (MODS), we included patients with hepatic, pulmonary and CNS dysfunction in this aPA study.
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Materials and methods
Patients
Citrated blood samples were drawn from patients who were admitted for bone marrow or peripheral blood hematopoietic stem cell transplantation at the University of Nebraska Medical Center. All samples were collected from patients before pretransplant chemo-radiation was initiated. The patients were monitored daily post-transplant until the time of discharge or death from MODS, defined by an ATIII activity of Ͻ84% plus dysfunction in one of the following three organ systems: (1) pulmonary, indicated by hypoxia determined by a finger oximeter showing O 2 saturation of Ͻ90% on two separate occasions at least 1 h apart; (2) central nervous system, indicated by a four point drop from baseline of the Mini-Mental State Exam; 31 and (3) hepatic, defined by bilirubin Ͼ2.0%, weight gain of Ͼ5% over baseline, and abdominal pain possibly of hepatic origin. The samples were from 57 patients who developed organ dysfunction following transplantation and 55 patients who underwent transplantation without developing organ dysfunction (controls). A total of 67 patients developed organ dysfunction. However, samples were available only for the 57 included in the study. Controls included in the study were matched to patients for age, gender, pretransplant chemo-radiation and transplant type.
Antiphospholipid antibody ELISA
In our Indianapolis laboratory, each patient is analyzed for aPA by using a panel format. Three phospholipids (PL) are used: cardiolipin (CL) and phosphatidylserine (PS), which are anionic, and phosphatidylethanolamine (PE) which is zwitterionic. Each PL is used to test for the presence of aPA in a plasma protein-dependent and a plasma proteinindependent assay. Each sample is evaluated for aPA to these six combinations of PL by using enzyme-antibody conjugates to human IgG, IgA and IgM. A patient is considered aPA positive when one or more of these 18 test results is above our predetermined positive control values. This assay is designed to detect antibodies which would not be detected by more traditional aPA ELISA assays which typically test only for IgG and/or IgM directed against CL. 7, 17, 32 Citrated plasmas from 112 patients were studied blindly for aPA by ELISA as previously described. 17 All plasmas were diluted separately (1:100) in 1% bovine serum albumin (BSA) for detection of plasma protein-independent aPA and in either 10% adult bovine serum (ABS) or 10% adult bovine plasma (ABP) for the detection of plasma protein-dependent aPA. The ABS is a source of plasma proteins for anionic phospholipids, such as ␤2 glycoprotein I 7,33 and prothrombin 7, 34 whereas the ABP is a source of plasma proteins for zwitterionic phospholipids, such as high and low molecular weight kininogen and the kininogen binding proteins, factor XI and prekallikrein. 7, 35 Samples diluted in 1% BSA were added to all PL plates and nonspecific binding (NSB) control plates; samples diluted in 10% ABS were added to the CL, PS and NSB control plates, and samples diluted in 10% ABP were added to the PE and NSB control plates. Positive and negative aPA control samples in 10% ABS were added to the CL, PS and NSB control plates, and control samples in 10% ABP were added to the PE and NSB control plates. NSB control plates contained no PL, and NSB control plate OD 410 values were subtracted from PL plate OD 410 values when NSB control values were у0.100.
Statistical analysis
Serum samples from 252 healthy people were tested previously by using the aPA ELISA to establish normal values for each PL antibody combination. 17 Patient results are reported as multiples of the mean (MoM) of OD 410 above the ELISA values obtained from the 252 controls. Results were defined as positive for aPA if they were greater than the MoM that encompassed 95% of the normal controls. 7, 36 Significance was determined by a 2 test with an alpha р0.05. The 95% confidence interval was calculated for the difference in proportions between groups.
Results
The aPA assays employed in this investigation can detect aPA reactivity both in the absence and presence of PLbinding plasma proteins, the latter being supplied in the patient sera diluent buffer. Table 1 lists the aPA-positive patients according to the PL, the isotype and whether the aPA reactivity was independent of PL-binding plasma proteins, dependent upon PL-binding plasma proteins or both. Seventeen of 112 patients, including 10 patients who developed MODS and seven control patients who did not develop MODS, were aPA positive. Many of these patients Table 1 aPA-positive patient profiles had multiple specificities. Table 2 lists the 10 aPA-positive patients with MODS according to the organ system in which dysfunction was first noted; many patients developed subsequent dysfunction in other organ systems. The number of aPA-positive patients with MODS (10/57) compared to the number of aPA-positive control patients without MODS (7/55) was not statistically significant (P = 0.48). No change in statistical significance was observed when plasma protein-independent aPA (P = 0.19) and plasma protein-dependent aPA (P = 0.64 by Fisher's exact test) were evaluated separately. The 95% confidence interval for the difference in aPA between MODS patients and control patients groups (−8% to 18%) includes zero.
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Discussion
For this study we considered patient-specific features such as age, gender, pretransplant chemo-radiation and transplant type to be irrelevant because our goal was to determine the incidence of aPA before conditioning in patients who developed MODS, including hepatic VOD, following BMT. In this study, incidence of aPA was not significantly increased in patients with MODS over the control patients without MODS. Power analysis for this study with a sample size of 112 and equated groups indicated sufficient power to rule out an association between aPA and MODS (1 − ␤ Х 0.90). For these patients, 17.5% with organ dysfunction and 12.7% of the control patients without organ dysfunction had aPA prior to pretransplant chemo-radiation. Because the 95% confidence interval for the difference in these proportions includes zero, it lends further support to the lack of a significant increase of aPA in patients with MODS compared to control patients without MODS. Additionally, when analyzing the incidence of MODS in aPA-positive patients compared to aPA-negative patients, 58.8% of the patients with aPA developed organ dysfunction while 49.5% of the patients without aPA developed organ dysfunction. The 95% confidence interval for the difference in these proportions (−16% to 35%) also includes zero.
Both patients with MODS and control patients without MODS in this study were derived from a group of patients with malignancy requiring BMT. An increased incidence of aPA has been demonstrated in patients with malignancy. 37 Using our aPA ELISA, Ͻ5% of healthy individuals tested were positive for aPA. 17, 32 The incidence of aPA-positive patients in this study (17/112 or 15.2%), including patients with MODS and control patients without MODS, compared to the number of aPA-positive healthy Table 2 aPA and organ dysfunction in MODS patients (n = 57) aPA positive (%) aPA negative (%) individuals is statistically significant (P Ͻ 0.002) and supports an earlier finding. 37 The most common aPA observed in this study were plasma protein-independent aPA. These types of aPA generally are considered transient, infection-related and nonpathogenic in contrast to the plasma protein-dependent aPA associated with autoimmune diseases. 38, 39 The patients in this study were clinically infection free prior to chemo-radiation and BMT; however, the transient nature of the aPA could not be determined as only one pre-chemo-radiation sample was available for aPA testing. Plasma protein dependence of aPA, however, may not always distinguish patients with complications from patients without complications. 40 Recently, plasma protein independent aPA have been detected in patients with early failed renal allografts and were found to be present historically. 15 The development of organ dysfunction is a common complication of BMT. Identification of those at risk for disease is important, regardless of the organ manifesting dysfunction. aPA present before pretransplant chemo-radiation do not appear to be a risk factor for the development of MODS subsequent to BMT in these bone marrow transplant patients. This, however, does not exclude the possibility of aPA involvement in organ dysfunction since the incidence of aPA may increase after conditioning and BMT. Investigation into the association of aPA present after BMT and organ dysfunction in bone marrow transplant recipients may be warranted.
